Hypertrophic obstructive cardiomyopathy in the setting of systemic scleroderma

Robert Sogomonian, Hassan Alkhawam, Feras Zaiem, Sunyoung Lee, M. Umair Bakhsh, Emma A. Moradoghli Haftevani, Dennis Chang

ABSTRACT

Introduction: The association of systemic sclerosis (SS) with restrictive cardiomyopathy has well been established, but that with hypertrophic obstructive cardiomyopathy (HOCM) is not clearly understood. Herein, we report a case of a patient with SS, identified to have both HOCM and myocardial fibrosis.

Case Report: A 54-year-old female with systemic sclerosis, idiopathic lung disease with moderate pulmonary hypertension, presented with fatigue, decreased appetite and shortness of breath. Cardiac magnetic resonance imaging (CMRI) was significant for both hypertrophic and restrictive cardiomyopathy. Cardiac biopsy revealed evidence of diffuse fibrosis.

Conclusion: Our case report describes an interesting association between SS and HOCM, as well as restrictive cardiomyopathy. However, more evidences are needed to clarify whether this unique affiliation is a coincidental random finding or a causative association.
Hypertrophic obstructive cardiomyopathy in the setting of systemic scleroderma

Robert Sogomonian, Hassan Alkhawam, Feras Zaiem, Sunyoung Lee, M. Umair Bakhsh, Emma A. Moradoghli Haftevani, Dennis Chang

ABSTRACT

Introduction: The association of systemic sclerosis (SS) with restrictive cardiomyopathy has well been established, but that with hypertrophic obstructive cardiomyopathy (HOCM) is not clearly understood. Herein, we report a case of a patient with SS, identified to have both HOCM and myocardial fibrosis. Case Report: A 54-year-old female with systemic sclerosis, idiopathic lung disease with moderate pulmonary hypertension, presented with fatigue, decreased appetite and shortness of breath. Cardiac magnetic resonance imaging (CMRI) was significant for both hypertrophic and restrictive cardiomyopathy. Cardiac biopsy revealed evidence of diffuse fibrosis. Conclusion: Our case report describes an interesting association between SS and HOCM, as well as restrictive cardiomyopathy. However, more evidences are needed to clarify whether this unique affiliation is a coincidental random finding or a causative association.

Keywords: Cardiac biopsy, Cardiomyopathy, Hypertrophic obstructive cardiomyopathy (HOCM), Lung disease, Pulmonary hypertension, Systemic sclerosis (SS)

INTRODUCTION

Restrictive cardiomyopathy has been a common variant seen in systemic sclerosis (SS) with myocardial fibrosis. An uncommon entity of hypertrophic obstructive cardiomyopathy (HOCM) has been described previously in only a very few cases of patients with systemic sclerosis. The association of SS with restrictive cardiomyopathy has well been established, but that with HOCM is not clearly understood. Herein, we report a case of a patient with SS, identified to have both HOCM and myocardial fibrosis. This singular case suggests that SS could be associated with HOCM, as well as restrictive cardiomyopathy.

CASE REPORT

A 54-year-old female with systemic sclerosis, idiopathic lung disease with moderate pulmonary hypertension, presented with fatigue, decreased appetite and shortness of breath. On admission, the patient became hypoxic with O₂ saturation of 86% on room air, tachycardic to 117 bpm, blood pressure of 110/53 mmHg.
Physical examination was significant for diffuse rhonchi in all lung fields, systolic murmurs, malar rash and skin excoriation in bilateral lower extremities without edema. Laboratory studies were significant for fingerstick glucose of 20 mg/dL with normal serum glucose, indicative of pseudohypoglycemia due to Raynaud’s phenomenon, and elevated brain natriuretic peptide (858 pg/mL). Transthoracic echocardiography revealed evidence of diastolic heart failure with a left ventricular ejection fraction of 78%. Electrocardiography illustrated left ventricular hypertrophy and sinus tachycardia.

Cardiac magnetic resonance imaging (CMRI) was significant for severe left ventricular cardiac asymmetric septal hypertrophy with outflow obstruction caused by anterior motion of mitral valve and pericardial effusion (Figure 1). Cardiac biopsy revealed evidence of diffuse fibrosis, but did not show iron, glycogen, or amyloid deposition (Figure 2).

She was initially treated for pneumonia and presumptive pulmonary embolism. She was aggressively diuresed with intravenous furosemide given clinical signs of hypervolemia followed by dehydration and hypotension to 80/54 mmHg. Intravenous normal saline hydration was provided with resolution of blood pressure.

Subsequently, initiated bosentan for presumptive concerns of pulmonary hypertension causing the symptoms however, symptoms worsened as patient was preload dependent and HOCM was exacerbated. Methylprednisolone was initiated, yet patient developed severe proteinuria and renal crisis in the setting of scleroderma. Patient was maintained on mycophenolate mofetil, lower dose of methylprednisolone, morphine, clonazepam and transferred to hospice care with risks, benefits and prognosis of further treatment explained.

**DISCUSSION**

Hypertrophic obstructive cardiomyopathy (HOCM) is the most common cardiac genetic disorder with an autosomal dominant transmission pattern. It is characterized by asymmetric left ventricular hypertrophy (LVH) out of proportion of systemic after load. The most common cardiac involvement in systemic sclerosis (SS) is myocardial fibrosis [1, 2], while HOCM is rarely seen in SS.

Genetically, a predisposition for HOCM with human lymphocyte antigen (HLA)-DR3 has been reported, and this may provide a possible link with SS as reported [3]. A possible autoimmune mechanism might be a good explanation of the unique association between HOCM and SS supported by the fact that HOCM has also been reported in many chronic hepatitis C virus infection; a disease with multiple extra-hepatic autoimmune manifestations [4].

Although myocardial fibrosis is the hallmark of primary myocardial involvement in SS, few previous studies reported an increased incidence of LVH or septal hypertrophy in patients with SS [2, 5]. A study of serial echocardiography for thirty patients with SS and 48 control objects had concluded that patients with SS have an increased LV wall thickness with impaired diastolic dysfunction, which may attribute to myocardial fibrosis [5]. Another study correlated the findings of echocardiography, electrocardiography, and autopsy in 95 patients with SS, who were monitored up to eight years [2]. Three patients have septal hypertrophy on autopsies. Echocardiography along with electrocardiography detects septal hypertrophy in 12 patients, six of whom had asymmetric septal hypertrophy. Out of these 12, ten had limited cutaneous SS involvement and only two was noted in the diffuse cutaneous SS pattern.
CONCLUSION

The association of systemic sclerosis (SS) with restrictive cardiomyopathy has been well established, but with hypertrophic obstructive cardiomyopathy (HOCM), is rarely reported. Our case report describes an interesting association between SS and HOCM, as well as restrictive cardiomyopathy. However, more evidences are needed to clarify whether this unique affiliation is a coincidental random finding or a causative association.

*********

Author Contributions

Robert Sogomonian – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Hassan Alkhawam – Analysis and interpretation of data, Final approval of the version to be published

Feras Zaiem – Analysis and interpretation of data, Final approval of the version to be published

Sunyoung Lee – Analysis and interpretation of data, Final approval of the version to be published

M. Umair Bakhsh – Analysis and interpretation of data, Final approval of the version to be published

Emma A. Moradoghli Haftevani – Analysis and interpretation of data, Final approval of the version to be published

Dennis Chang – Analysis and interpretation of data, Final approval of the version to be published

Guarantor

The corresponding author is the guarantor of submission.

Conflict of Interest

Authors declare no conflict of interest.

Copyright

© 2015 Robert Sogomonian et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES

Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.

Most Favored Author program
Join this program and publish any number of articles free of charge for one to five years.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

We welcome you to interact with us, share with us, join us and of course publish with us.

CONNECT WITH US

Edorium Journals: On Web
Browse Journals

This page is not a part of the published article. This page is an introduction to Edorium Journals and the publication services.